Insect Cell, Per Se Patents (Class 435/348)
  • Publication number: 20140328875
    Abstract: Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.
    Type: Application
    Filed: December 17, 2013
    Publication date: November 6, 2014
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer
  • Publication number: 20140325711
    Abstract: The present invention relates to isolated polypeptides having lysozyme activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: November 23, 2012
    Publication date: October 30, 2014
    Inventors: Kirk Matthew Schnorr, Jens Erik Nielsen, Mikkel Klausen
  • Publication number: 20140325692
    Abstract: The present invention provides methods for light-dependent gene regulation using a light-responsive DNA-binding protein. Also provided are related nucleic acid molecules, and protein molecules, such as those encoding or comprising the light-responsive DNA-binding protein or DNA-binding sites recognizing the light-responsive DNA-binding protein. Kits using the present light-dependent gene regulation system are further provided by the present invention.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 30, 2014
    Inventors: Kevin H. Gardner, Laura B. Motta-Mena, Brian D. Zotowski
  • Publication number: 20140323348
    Abstract: Disclosed are methods of promoting and/or enhancing G-Protein Coupled Receptor (GPCR) localization to the cell membrane and/or cell surface; methods of promoting and/or enhancing GPCR functional expression; and methods and assays for screening or identifying ligands (e.g., agonists or antagonists) that bind GPCRs. Also provided are vectors, recombinant cells, and stable cell lines for use in the methods and assays.
    Type: Application
    Filed: November 30, 2012
    Publication date: October 30, 2014
    Inventors: Hiroaki Matsunami, Yue Jiang, Ming-Shan Chien
  • Publication number: 20140323401
    Abstract: The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor.
    Type: Application
    Filed: April 8, 2014
    Publication date: October 30, 2014
    Applicant: Araim Pharmaceuticals, Inc.
    Inventors: Anthony CERAMI, Michael BRINES, Thomas COLEMAN
  • Publication number: 20140322753
    Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
    Type: Application
    Filed: June 30, 2014
    Publication date: October 30, 2014
    Inventors: Paul Harris, Elena Vlasenko, Marcus Sakari Kauppinnen, Elizabeth Zaretsky, Sarah Teter, Kimberly Brown
  • Publication number: 20140322770
    Abstract: The present invention relates to isolated polypeptides having peroxygenaseactivity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: November 28, 2012
    Publication date: October 30, 2014
    Inventors: Sara Landvik, Lars Henrik Oestergaard, Lisbeth Kalum
  • Publication number: 20140322812
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Application
    Filed: April 24, 2014
    Publication date: October 30, 2014
    Applicant: Intrexon Corporation
    Inventors: Subba Reddy PALLI, Mohan Basavaraju KUMAR
  • Publication number: 20140322807
    Abstract: Processes for extracting and recovering nutrients from organic wastes to create a cell culture broth for microorganisms involve the main steps of mixing, solid/liquid separation, optimization, and sterilization. In an embodiment, the method for converting organic waste material into a cell culture broth or growth media includes: (a) mixing an organic waste material with one or more solvent to create a mixture of liquids and solids under substantially turbulent conditions; (b) separating the mixture of liquids and solids into a liquid stream and solid stream; and (c) sterilizing the liquid stream, whereby the cell culture broth or growth media comprises the sterilized liquid stream.
    Type: Application
    Filed: December 6, 2012
    Publication date: October 30, 2014
    Applicant: INNOVATIVE BIOS L.L.C.
    Inventors: John Paul Gustin, Jason Allen Repac
  • Publication number: 20140322768
    Abstract: The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: November 28, 2012
    Publication date: October 30, 2014
    Inventors: Sara Landvik, Lars Henrik Oestergaard, Lisbeth Kalum
  • Publication number: 20140315310
    Abstract: The invention provides, inter alia, recombinase-based systems that provide for integrated logic and memory in living cells.
    Type: Application
    Filed: December 13, 2013
    Publication date: October 23, 2014
    Applicant: Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Piro Siuti
  • Publication number: 20140315804
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 23, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
  • Publication number: 20140317786
    Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 23, 2014
    Inventor: Marc Morant
  • Publication number: 20140315299
    Abstract: The invention provides a fusion protein comprising, from N-terminus to C-terminus: a) a first portion of a Family B G-protein coupled receptor (GPCR) that comprises transmembrane helix (TM)-1, TM2 and TM3 of the GPCR; b) a stable protein domain; and c) a second portion of the GPCR comprising TM4, TM5, TM6 and TM7 of the GPCR. The invention also provides a method of crystallising a GPCR comprising providing the fusion protein of the invention and crystallising it to obtain crystals.
    Type: Application
    Filed: August 9, 2012
    Publication date: October 23, 2014
    Applicant: Heptares Therapeutics Limited
    Inventors: Seyed Ali Jazayeri-Dezfuly, Fiona Hamilton Marshall
  • Publication number: 20140309400
    Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of dry eye syndrome.
    Type: Application
    Filed: November 30, 2012
    Publication date: October 16, 2014
    Inventors: Jean-Marc Combette, Catherine Deloche
  • Publication number: 20140308247
    Abstract: This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing one or more proteins under the control of a gene expression modulation, system in the presence of activating ligand and uses for therapeutic purposes in animals. The vector may be provided to treat or prevent disease.
    Type: Application
    Filed: March 2, 2012
    Publication date: October 16, 2014
    Applicant: Intrexon Corporation
    Inventors: Jeremiah F. Roeth, Brandon Cuthbertson, Charles C. Reed, Sunil Chada, William E. Fogler, Fayas Khazi
  • Publication number: 20140308291
    Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides methods of inducing an immune response against a panton-valentine leukocidin (PVL)-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.
    Type: Application
    Filed: November 30, 2012
    Publication date: October 16, 2014
    Inventors: Mohammad Javad Aman, Rajan Prasad Adhikari, Hatice Karauzum, Jawad Sarwar, Sergey Shulenin, Sathya Venkataramani, Kelly Lyn Warfield, Tam Luong Nguyen
  • Publication number: 20140308266
    Abstract: The present invention is concerned with modified neurotoxins. Specifically, it relates to a modified biologically active neurotoxin polypeptide comprising at least one poly-Glycine domain. Also contemplated is a polynucleotide encoding the modified neurotoxin polypeptide having a poly-Glycine domain fused to the N-terminus, to the C-terminus or to both of the heavy and/or light chain of the mature neurotoxin polypeptide, vector comprising it and a host cell comprising such a polynucleotide or a vector. Moreover, envisaged are the aforementioned compounds for use as a medicament for treating various diseases.
    Type: Application
    Filed: November 8, 2012
    Publication date: October 16, 2014
    Inventor: Karl-Heinz Eisele
  • Patent number: 8859240
    Abstract: The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre-m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: October 14, 2014
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Frédéric Tangy, Philippe Despres, Chantal Combredet, Marie Pascale Frenkiel
  • Publication number: 20140302561
    Abstract: The present invention relates in particular to proteins, coding nucleic acid sequences for same, vectors comprising said coding sequences, a method for producing said proteins, and an oligosaccharide hydrolysis method using same. In particular, the invention relates to the protein of sequence SEQ ID no. 1. The present invention can be applied to the recycling of bio-natural resources formed by organisms and microorganisms including ulvans, in particular green algae.
    Type: Application
    Filed: September 14, 2012
    Publication date: October 9, 2014
    Applicants: UNIVERSITÉ PIERRE ET MARIE CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE- CNRS, CENTRE D'ÉTUDE ET DE VALORISATION DES ALGUES
    Inventors: Pi Collen, William Helbert, Yannick Lerat, Jean-François Sassi
  • Publication number: 20140303084
    Abstract: Provided are pro-coagulant compounds (e.g., pro-coagulant peptides or peptide derivatives) and methods of using and making those compounds. Further provided are conjugates between a pro-coagulant compound of the present disclosure (e.g., pro-coagulant peptide or peptide derivative) and a polypeptide selected from FIX, FVIIa, FVIII, and platelet targeting moieties (e.g., PDG-13), wherein the compound is linked to the polypeptide optionally via a linker. The compounds and conjugates are useful for the treatment of coagulation disorders, such as hemophilia A and hemophilia B. Further provided are methods of using and making the conjugates.
    Type: Application
    Filed: June 9, 2012
    Publication date: October 9, 2014
    Applicant: Biogen IDEC MA Inc.
    Inventors: Karina Thorn, Garabet G. Toby, Adam R. Mezo
  • Publication number: 20140304859
    Abstract: Provided are isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: December 14, 2012
    Publication date: October 9, 2014
    Applicant: Novozymes Inc.
    Inventors: Ye Liu, Yu Zhang, Junxin Duan, Lan Tang
  • Publication number: 20140302076
    Abstract: The present invention provides compositions relating to viral capsomeres which comprise foreign immunogenic sequences for use in pharmaceutical compositions and methods of producing such compositions, and related isolated or purified protein and nucleic acid molecules, vectors, host cells, compositions, and methods of use to augment an immune response, immunise an animal and prophylactically or therapeutically treat a disease, disorder or condition. The viral capsomere may be derived from a polyomavirus and comprise an immunogen of interest at the N-terminus and further at the C-terminus and/or at one or more exposed loops of the capsomere.
    Type: Application
    Filed: August 13, 2012
    Publication date: October 9, 2014
    Applicant: THE UNIVERSITY OF QUEENSLAND
    Inventors: Anton Peter Jacob Middelberg, Linda Hwee-Lin Lua
  • Publication number: 20140302495
    Abstract: The present invention relates to a novel tail spike protein (TSP) encoded by the novel Listeria bacteriophage designated ProCC P825 and uses of the novel TSP for identifying, detecting and monitoring of Listeria.
    Type: Application
    Filed: May 29, 2012
    Publication date: October 9, 2014
    Applicant: BIOMERIEUX SA
    Inventors: Holger Grallert, Sonja Molinaro, Julia Lorenz
  • Patent number: 8853154
    Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: October 7, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Hui Wei, Aaron P. Yamniuk, Vidhyashankar Ramamurthy, Alexander T. Kozhich, Martin J. Corbett, Stanley Richard Krystek, Jr.
  • Publication number: 20140295544
    Abstract: The present invention relates to fluorescent proteins, in particular green fluorescent proteins (GFPs), with increased activity in cells, and thus increased signal strength. A further aspect of the present invention relates to the use of peptides for increasing the expression and/or stability of a protein in a cell.
    Type: Application
    Filed: June 13, 2014
    Publication date: October 2, 2014
    Inventor: Khalid S. Abu KHABAR
  • Publication number: 20140295457
    Abstract: The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.
    Type: Application
    Filed: October 11, 2012
    Publication date: October 2, 2014
    Inventors: Mark Broenstrup, Claudia Koenig, Luigi Toti, Joachim Wink, Wulf Leuschner, Johann Gassenhuber, Rolf Müller, Silke Wenzel, Tina Binz, Carsten Volz
  • Publication number: 20140298499
    Abstract: The invention relates to enzymes having xylanase, mannanase and/or glucanase activity, e.g., catalyzing hydrolysis of internal ?-1,4-xylosidic linkages or endo-?-1,4-glucanase linkages; and/or degrading a linear polysaccharide beta-1,4-xylan into xylose. Thus, the invention provides methods and processes for breaking down hemicellulose, which is a major component of the cell wall of plants, including methods and processes for hydrolyzing hemicelluloses in any plant or wood or wood product, wood waste, paper pulp, paper product or paper waste or byproduct. In addition, methods of designing new xylanases, mannanases and/or glucanases and methods of use thereof are also provided. The xylanases, mannanases and/or glucanases have increased activity and stability at increased pH and temperature.
    Type: Application
    Filed: December 16, 2013
    Publication date: October 2, 2014
    Applicant: BP Corporation North America Inc.
    Inventors: Kevin A. Gray, Reinhard Dirmeier
  • Publication number: 20140298505
    Abstract: The present invention relates to a nucleic acid molecule encoding (I) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of SEQ ID NO: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein T is replaced by U; (II) a fragment of the polypeptide of (I) having the activity of an endonuclease.
    Type: Application
    Filed: June 6, 2012
    Publication date: October 2, 2014
    Inventor: Ralf Kühn
  • Publication number: 20140295502
    Abstract: The present invention generally relates to methods of making cDNA molecules and cDNA libraries. The invention also relates to cDNA molecules and cDNA libraries produced according to these methods, as well as to vectors and host cells containing such cDNA molecules and libraries. The invention also relates to kits for making the cDNA molecules and libraries of the invention.
    Type: Application
    Filed: May 13, 2014
    Publication date: October 2, 2014
    Inventors: Wu-Bo LI, Joel Jessee, Christian Gruber
  • Publication number: 20140294801
    Abstract: The present invention provides an improved and specific mRNA interferase and related methods of protein-based mRNA interference.
    Type: Application
    Filed: August 3, 2012
    Publication date: October 2, 2014
    Applicant: Rutgers, The State University of New Jersey
    Inventors: Masayori Inouye, Yoshihiro Yamaguchi
  • Publication number: 20140295543
    Abstract: The present invention concerns methods and compositions involving RNase III and polypeptides containing RNase III domains to generate RNA capable of triggering RNA-mediated interference (RNAi) in a cell. In some embodiments, the RNase III is from a prokaryote. RNase III activity will cleave a double-stranded RNA molecule into short RNA molecules that may trigger or mediate RNAi (siRNA). Compositions of the invention include kits that include an RNase III domain-containing polypeptide. The present invention further concerns methods using polypeptides with RNase III activity for generating RNA molecules that effect RNAi, including the generation of a number of RNA molecules to the same target.
    Type: Application
    Filed: December 16, 2013
    Publication date: October 2, 2014
    Applicant: APPLIED BIOSYSTEMS, LLC
    Inventors: Lance FORD, David BROWN
  • Publication number: 20140294879
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 2, 2014
    Applicant: NOVAVAX, INC.
    Inventors: Peter PUSHKO, Yingyun WU, Michael J. MASSARE, Ye LIU, Gale SMITH, Bin ZHOU
  • Publication number: 20140294773
    Abstract: A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cas6 which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity. The Cascade complex with additional activity is combined with an RNA molecule to produce a ribonucleoprotein complex. The RNA molecule is selected to have substantial complementarity to a target sequence. Targeted ribonucleoproteins can be used as genetic engineering tools for precise cutting of nucleic acids in homologous recombination, non-homologous end joining, gene modification, gene integration, mutation repair or for their visualisation, transcriptional activation or repression.
    Type: Application
    Filed: December 21, 2012
    Publication date: October 2, 2014
    Inventors: Stan Johan Jozef Brouns, John Van Der Oost
  • Publication number: 20140295556
    Abstract: Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 2, 2014
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: J. Keith Joung, Shengdar Tsai
  • Publication number: 20140296324
    Abstract: The present disclosure describes nucleic acids, and viruses comprising such nucleic acids, for growing a toxic gene in an insect cell. These nucleic acids comprise a sequence encoding a toxic polypeptide, and an intron that interrupts the sequence, whereby the intron is spliced in mammalian cells but not in insect cells. Infection of mammalian cells but not insect cells with the nucleic acids or viruses can lead to expression of toxic levels of the toxic polypeptide in mammalian cells but not in insect cells. Viruses, such as an AAV or a baculovirus comprising a nucleic acid can be grown in insect cell lines in vitro and can be administered to a subject in need of therapy, such as a subject in need of cancer therapy.
    Type: Application
    Filed: October 16, 2012
    Publication date: October 2, 2014
    Applicant: Virovek Incorporation
    Inventor: Haifeng Chen
  • Publication number: 20140295496
    Abstract: The present invention provides a recombinant baculovirus. The baculovirus has a genome into which a gene encoding ?-glutamyl carboxylase (GGCX) and a gene encoding DT-diaphorase (NQO1) are incorporated. The present invention further provides a method for producing a recombinant vitamin K-dependent protein by using the recombinant baculovirus.
    Type: Application
    Filed: March 27, 2014
    Publication date: October 2, 2014
    Applicant: SYSMEX CORPORATION
    Inventors: Takahiko BANDO, Mutsumi SUGAI
  • Patent number: 8846373
    Abstract: The present invention relates to new methods to promote sialylation of glycoconjugates, including recombinant glycoproteins, in glycoconjugate production systems. The invention relates to methods to promote efficient glycoconjugate sialylation in recombinant expression systems, by providing simpler and more economical ways to produce large intracellular pools of sialic acid precursors. The invention is directed to nucleic acids, vectors, and cells harboring vectors comprising nucleic acids encoding enzymes involved in the synthesis of sialic acid precursors, and cells harboring these nucleic acids in combination with nucleic acids encoding glycosyltransferases, including sialyltransferases, to facilitate the production of humanized recombinant glycoproteins in bacterial, fungal, plant, and animal cell expression systems.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: September 30, 2014
    Assignee: The University of Wyoming
    Inventors: Christoph Geisler, Donald Jarvis
  • Patent number: 8846886
    Abstract: A transgenic insect cell line for production of elevated levels of recombinant glycoproteins comprising mammalian-like N-glycans is provided. Also disclosed are nucleic acid sequences encoding ?-N-acetylglucosaminidases.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: September 30, 2014
    Assignee: University of Wyoming
    Inventors: Donald L. Jarvis, Christoph Geisler
  • Publication number: 20140288008
    Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 25, 2014
    Applicants: Daiichi Sankyo Company, Limited, Pieris AG
    Inventors: GABRIELE MATSCHINER, CHRISTINE ROTHE, ANDREAS HOHLBAUM, ANDREA ALLERSDORFER, RACHIDA SIHAM BEL AIBA, MARLON HINNER, ALEXANDER WIEDENMANN, SHINJI YAMAGUCHI, TAKAHIDE ABURATANI, RYUJI HASHIMOTO, TOHRU TAKAHASHI, CHIKAKO NAGASAKI, FUTOSHI NARA, TOMOHIRO NISHIZAWA
  • Publication number: 20140289905
    Abstract: Provided are isolated polypeptides having xylanase activity, catalytic domains and cellulose binding domains, and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains.
    Type: Application
    Filed: November 9, 2012
    Publication date: September 25, 2014
    Applicant: Novozymes Inc.
    Inventors: Yu Zhang, Junxin Duan, Ye Liu, Lan Tang
  • Publication number: 20140287465
    Abstract: The present invention relates to polypeptides having xylanase activity, catalytic domains, and carbohydrate binding domains, and polynucleotides encoding the polypeptides, catalytic domains, and carbohydrate binding domains. The present invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains, and carbohydrate binding domains.
    Type: Application
    Filed: December 18, 2012
    Publication date: September 25, 2014
    Inventors: Nikolaj Spodsberg, Tarana Shaghasi
  • Publication number: 20140287460
    Abstract: The present invention describes a novel method for recombinant protein production using a baculovirus protein expression system in insect cells, wherein baculovirus virion production is suppressed during recombinant protein production. The novel expression system produces reduced levels of baculovirus virions during recombinant protein production phase, thereby reducing the need for purification of the recombinant protein from the contaminating virus. The novel baculovirus expression system may further suppress expression of recombinant protein by baculovirus-infected cells during virus amplification prior to induction, thereby reducing selection pressure on the expression cassette for the recombinant protein.
    Type: Application
    Filed: July 26, 2012
    Publication date: September 25, 2014
    Applicant: GBIOTECH SARL
    Inventor: Daniel J. FITZGERALD
  • Publication number: 20140273204
    Abstract: The invention relates to recombinant expression vectors encoding a low molecular weight peptide isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Inventors: John M. Stewart, Bradley J. Steeves, Karl Vernes
  • Publication number: 20140273205
    Abstract: The present invention provides serum-free cell culture media formulations which are capable of supporting the in vitro cultivation of animal cells. The media comprise at least one nutrient of non-animal derivation, such as at least one plant peptide and/or at least one non-animal or plant lipid and/or fatty acid. The media may further optionally comprise an enzymatic digest or extract of yeast cells. The present invention also provides methods of cultivating animal cells in vitro using these cell culture media formulations. In addition, the media of the present invention can be used for growth of animal cells for virus production.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Paul PRICE, Stephen GORFIEN, Douglas DANNER, Mark PLAVSIC
  • Publication number: 20140271700
    Abstract: Described herein are isolated polypeptides each containing one or more receptor-binding sites of toxin A (tcdA) of Clostridium difficile (Cd), nucleic acids encoding the polypeptides, and methods of using the polypeptides and nucleic acids.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: National Health Research Institutes
    Inventors: Pele Choi-Sing Chong, Jui-Hsin Huang, Chih-Hsiang Leng
  • Publication number: 20140273089
    Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The inventio further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L polypeptides.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Applicant: AMGEN, INC.
    Inventors: Christiaan M. Saris, Sharon X. Mu, Min Xia, Thomas Charles Boone, Todd Covey
  • Publication number: 20140283154
    Abstract: The present invention relates to methods of facilitating the expression of recombinant polypeptides from cells, extracellular fluids, extracellular fibers, or any combination thereof, obtained from transgenic insect cells and larvae comprising a bacterial GlcNAc-6-P 2?-epimerase (GNPE), which is capable of converting N-acetyl-D-glucosamine-6-phosphate (GlcNAc-6-P) to N-acetyl-D-mannosamine-6-phosphate (ManNAc-6-P). The invention relates to methods to promote efficient glycoconjugate sialylation, by providing simpler ways to produce large intracellular pools of sialic acid precursors. The invention is also directed to nucleic acids, vectors, and cells comprising nucleic acids encoding polypeptides involved in the synthesis of sialic acid precursors, and cells in combination with nucleic acids encoding glycosyltransferases, including sialyltransferases, to facilitate the production of humanized recombinant glycoproteins.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Inventors: Christoph GEISLER, Donald Jarvis
  • Publication number: 20140273144
    Abstract: Provided herein are compositions and methods for improved production of acetyl-CoA and acetyl-CoA derived compounds in a host cell. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding a phosphoketolase (PK), and a functional disruption of an endogenous enzyme that converts acetyl phosphate to acetate. In some embodiments, the host cell further comprises a heterologous nucleotide sequence encoding a phosphotransacetylase (PTA). In some embodiments, the enzyme that converts acetyl phosphate to acetate is a glycerol-1-phosphatase. In some embodiments, the glycerol-1-phosphatase is GPP1/RHR2. In some embodiments, the glycerol-1-phosphatase is GPP2/HOR2. The compositions and methods described herein provide an efficient route for the heterologous production of acetyl-CoA-derived compounds, including but not limited to, isoprenoids, polyketides, and fatty acids.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Kristy Michelle Hawkins, Tina Tipawan Mahatdejkul-Meadows, Adam Leon Meadows, Lauren Barbara Pickens, Anna Tai, Annie Ening Tsong
  • Publication number: 20140274782
    Abstract: Methyl-lysine affinity reagents created by engineering the 3×MBT methyl-lysine binding domain repeat of lethal (3) malignant brain tumor-like protein 1 (L3MBTL1) are disclosed. In particular, the invention relates to affinity reagents and affinity chromatography media comprising the 3×MBT domain repeat and methods of using such affinity reagents in detection, purification, and proteomic profiling of methylated proteins and peptides.
    Type: Application
    Filed: March 15, 2014
    Publication date: September 18, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Scott M. Carlson, Or Gozani, Kaitlyn E. Moore